Study treatments
Neurotidine®
DISEASE
Patients were treated with any IOP-lowering agent to control the disease. Patients were randomized to a citicoline 50 mg/ml oral solution-placebo or placebo-citicoline 50 mg/ml oral solution sequence and received treatment for 3 months in the first period and for 6 months in the second period of the cross-over design. The second period was extended to 6 months to control for a potential carry-over effect in the group receiving citicoline oral solution in the first period of the cross-over design.Two identical bottles contained either 500 ml of citicoline oral solution (Neurotidine®, Omikron Italia srl), citicoline free acid 50 mg/ml; water; fructose; acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; color: riboflavin; or placebo 500 ml oral solution, water; fructose; sucralose; acidity regulators: sodium citrate, anhydrous citric acid, sodium hydroxide; preservative: potassium sorbate; color: riboflavin. Citicoline oral solution or placebo were administered at a dosage of 10 ml (500 mg of citicoline/day) in the morning.